CA3098262C - Agents cryoprotecteurs pour formulations particulaires - Google Patents

Agents cryoprotecteurs pour formulations particulaires

Info

Publication number
CA3098262C
CA3098262C CA3098262A CA3098262A CA3098262C CA 3098262 C CA3098262 C CA 3098262C CA 3098262 A CA3098262 A CA 3098262A CA 3098262 A CA3098262 A CA 3098262A CA 3098262 C CA3098262 C CA 3098262C
Authority
CA
Canada
Prior art keywords
composition
mrna
nucleic acid
nano
cationic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3098262A
Other languages
English (en)
Other versions
CA3098262A1 (fr
Inventor
Christian Dohmen
Philipp Beck
Original Assignee
Ethris GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethris GmbH filed Critical Ethris GmbH
Priority claimed from PCT/EP2019/060646 external-priority patent/WO2019207061A1/fr
Publication of CA3098262A1 publication Critical patent/CA3098262A1/fr
Application granted granted Critical
Publication of CA3098262C publication Critical patent/CA3098262C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne une composition comprenant (i) une formulation de nano- ou microparticules d'un agent thérapeutiquement actif qui est en suspension dans une phase liquide, et (ii) au moins un additif cryoprotecteur choisi parmi les alcanes en C3-C5 substitués par un ou deux groupes hydroxy qui stabilise la formulation de particules. D'autres aspects concernent une composition solide qui peut être obtenue par congélation de la composition stabilisée, et des procédés pour la préparation des compositions conformes à l'invention.
CA3098262A 2018-04-25 2019-04-25 Agents cryoprotecteurs pour formulations particulaires Active CA3098262C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18169325.0 2018-04-25
EP18169325 2018-04-25
EP18189010.4 2018-08-14
EP18189010 2018-08-14
PCT/EP2019/060646 WO2019207061A1 (fr) 2018-04-25 2019-04-25 Agents cryoprotecteurs pour formulations particulaires

Publications (2)

Publication Number Publication Date
CA3098262A1 CA3098262A1 (fr) 2019-10-31
CA3098262C true CA3098262C (fr) 2025-08-26

Family

ID=

Similar Documents

Publication Publication Date Title
AU2019258679B2 (en) Cryoprotective agents for particulate formulations
US20240156729A1 (en) Formulations for aerosol formation and aerosols for the delivery of nucleic acid
Köping‐Höggård et al. Relationship between the physical shape and the efficiency of oligomeric chitosan as a gene delivery system in vitro and in vivo
CA2971284C (fr) Compositions pour l'introduction d'acide nucleique dans des cellules
US20030138407A1 (en) Therapeutic methods for nucleic acid delivery vehicles
BR112015032225B1 (pt) Composição, composição farmacêutica, uso de uma composição, e, método in vitro para dispensação de rna de fita simples a uma célula alvo ou tecido
JPH09508100A (ja) 核酸を含む組成物、調製および使用
Abdullah et al. Gene transfer into the lung by nanoparticle dextran‐spermine/plasmid DNA complexes
JP2024516164A (ja) 正確なインビボｈｄｒ介在性遺伝子編集を可能にするオールインワンデンドリマーベース脂質ナノ粒子
Roques et al. Comparison of toxicity and transfection efficiency of amphiphilic block copolymers and polycationic polymers in striated muscles
EP4327829A1 (fr) Stabilisation de suspensions de nanoparticules lipidiques ou lipidoïdes
CA3098262C (fr) Agents cryoprotecteurs pour formulations particulaires
EP3836903B1 (fr) Formulations à base de lipides contenant des sels pour l'administration d'arn
RU2820713C2 (ru) Криопротективные агенты для содержащих частицы составов
EP4306133A1 (fr) Composition pour l'administration de structures oligonucléotidiques bicaténaires à l'aide d'un nébuliseur à ultrasons pour la prévention ou le traitement d'une infection virale respiratoire, y compris la covid-19, de la fibrose pulmonaire provoquée par une infection virale, ou de maladies respiratoires
Zhang et al. Charge-Engineered Lipid Nanoparticles with Poly (γ-glutamic acid) for Improved CRISPR/Cas9 Genome Editing
HK40105394A (en) Composition for administration of double-stranded oligonucleotide structures using ultrasonic nebulizer for prevention or treatment of respiratory viral infection including covid-19, pulmonary fibrosis caused by viral infection, or respiratory diseases
WO2023089183A1 (fr) Composition comprenant un agent thérapeutiquement actif enrobé dans un véhicule d'administration de médicament
Abdullah et al. Research Article Gene Transfer into the Lung by Nanoparticle Dextran-Spermine/Plasmid DNA Complexes